A new study showed that adding TSI Group's proprietary processed PUREFLEX® brand low molecular weight chondroitin sulfate to a glucosamine sulfate regimen provided a statistically significant reduction in loss of knee cartilage. The randomized, double-blind and placebo-controlled Long-Term Evaluation of Glucosamine Sulfate (LEGS) study evaluated 605 subjects at the University of Sydney, Australia and was published last month by the BMJ Group.
The cartilage loss was measured as knee joint space narrowing (JSN). After two years of once-daily treatment with 1500 mg of glucosamine and 800 mg of TSI’s chondroitin, the reduction in JSN was approximately half of that demonstrated in the placebo group. Consumer's with knee joint issues currently are without a helpful product—and, to date, have been without a proven method of slowing the progression of the knee condition from loss of cartilage. "These findings have exciting implications for knee joint sufferers," said TSI Group's CEO Joe Zhou. "We're enthusiastic about the potential of PUREFLEX chondroitin as a tool in protecting knee joints."
The study also noted that the structural benefits could not be felt and occurred independent of any minor pain relief benefit reported.
Jason Theodosakis, MD, MS, MPH, associate professor, researcher, and author of the number-one best-seller The Arthritis Cure, was the first to theorize a synergistic effect of glucosamine and chondroitin. Dr. Theodosakis calls the LEGS study "large and well designed," and says it is "very strong evidence for structure modification of cartilage, a 'holy grail' in the care of those with joint problems."
Dr. Theodosakis advises consumers to "beware of companies claiming their products, which don't have any structural evidence or long-term safety data, are somehow 'more effective' than glucosamine and chondroitin, as they are not. It's dangerous and harmful to try to steer people away from glucosamine and chondroitin since these are the only supplements to have multiple, long-term, structure benefits and long-term safety data."
There were no differences in adverse events in those taking the glucosamine–chondroitin combination versus placebo, adding to the already substantial body of data indicating the excellent safety of both ingredients.